Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens

Vaccine

Volumn 28, Issue 26, 2010, Pages 4275-4282

  Lambeck, Annechien J A ^a   Nijman, Hans W ^a   Hoogeboom, Baukje Nynke ^a   Regts, Joke ^a   de Mare, Arjan ^a   Wilschut, Jan ^a   Daemen, Toos ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Semliki Forest virus; T cell competition; Viral vector

Indexed keywords

BETA GALACTOSIDASE; OVALBUMIN; VIRUS ENZYME; VIRUS NUCLEOPROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CELL ACTIVITY; CELL STRAIN BHK; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; INFLUENZA VIRUS; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEMLIKI FOREST ALPHAVIRUS; VIRUS RECOMBINANT; VIRUS STRAIN; WART VIRUS;

ANIMALS; ANTIBODY SPECIFICITY; CELL LINE; CRICETINAE; EPITOPES; FEMALE; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE; PAPILLOMAVIRIDAE; RNA REPLICASE; SEMLIKI FOREST VIRUS; T-LYMPHOCYTES, CYTOTOXIC; TRANSGENES;

EID: 77952742185     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.033     Document Type: Article

References (42)

1. Harrop R., and Carroll M.W. Viral vectors for cancer immunotherapy. Front Biosci 11 (2006) 804-817
2. Mingozzi F., Maus M.V., Hui D.J., Sabatino D.E., Murphy S.L., Rasko J.E., et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13 4 (2007) 419-422
3. Petry H., Brooks A., Orme A., Wang P., Liu P., Xie J., et al. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice. Gene Ther 15 (2007) 54-60
4. Harrop R., John J., and Carroll M.W. Recombinant viral vectors: cancer vaccines. Adv Drug Deliv Rev 58 8 (2006) 931-947
5. Daemen T., Regts J., Holtrop M., and Wilschut J. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther 9 2 (2002) 85-94
6. Daemen T., Riezebos-Brilman A., Bungener L., Regts J., Dontje B., and Wilschut J. Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine 21 11-12 (2003) 1082-1088
7. Daemen T., Riezebos-Brilman A., Regts J., Dontje B., van der Zee A., and Wilschut J. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther 9 5 (2004) 733-742
8. de Mare A., Lambeck A.J., Regts J., van Dam G.M., Nijman H.W., Snippe H., et al. Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition. Gene Ther 15 (2007) 393-403
9. Sundback M., Douagi I., Dayaraj C., Forsell M.N., Nordstrom E.K., McInerney G.M., et al. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles. Virology 341 2 (2005) 190-202
10. Naslund T.I., Uyttenhove C., Nordstrom E.K., Colau D., Warnier G., Jondal M., et al. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J Immunol 178 11 (2007) 6761-6769
11. Butz E.A., and Bevan M.J. Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity 8 2 (1998) 167-175
12. Crowe S.R., Turner S.J., Miller S.C., Roberts A.D., Rappolo R.A., Doherty P.C., et al. Differential antigen presentation regulates the changing patterns of CD8+ T cell immunodominance in primary and secondary influenza virus infections. J Exp Med 198 3 (2003) 399-410
13. La Gruta N.L., Kedzierska K., Pang K., Webby R., Davenport M., Chen W., et al. A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies. Proc Natl Acad Sci USA 103 4 (2006) 994-999
14. Palmowski M.J., Choi E.M., Hermans I.F., Gilbert S.C., Chen J.L., Gileadi U., et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 168 9 (2002) 4391-4398
15. Rodriguez F., Harkins S., Slifka M.K., and Whitton J.L. Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. J Virol 76 9 (2002) 4251-4259
16. Berglund P., Fleeton M.N., Smerdou C., and Liljestrom P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 17 5 (1999) 497-507
17. Daemen T., Pries F., Bungener L., Kraak M., Regts J., and Wilschut J. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther 7 21 (2000) 1859-1866
18. Moore M.W., Carbone F.R., and Bevan M.J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54 6 (1988) 777-785
19. Liljestrom P., and Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (NY) 9 12 (1991) 1356-1361
20. Huckriede A., Bungener L., Holtrop M., de Vries J., Waarts B.L., Daemen T., et al. Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming. Vaccine 22 9-10 (2004) 1104-1113
21. Haanen J.B., Toebes M., Cordaro T.A., Wolkers M.C., Kruisbeek A.M., and Schumacher T.N. Systemic T cell expansion during localized viral infection. Eur J Immunol 29 4 (1999) 1168-1174
22. Bungener L., Huckriede A., de Mare A., Vries-Idema J., Wilschut J., and Daemen T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 23 10 (2005) 1232-1241
23. Hidmark A.S., McInerney G.M., Nordstrom E.K., Douagi I., Werner K.M., Liljestrom P., et al. Early alpha/beta interferon production by myeloid dendritic cells in response to UV-inactivated virus requires viral entry and interferon regulatory factor 3 but not MyD88. J Virol 79 16 (2005) 10376-10385
24. Wang J., Mauser A., Chao S.F., Remington K., Treckmann R., Kaiser K., et al. Virus inactivation and protein recovery in a novel ultraviolet-C reactor. Vox Sang 86 4 (2004) 230-238
25. Riezebos-Brilman A., Regts J., Freyschmidt E.J., Dontje B., Wilschut J., and Daemen T. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther 12 18 (2005) 1410-1414
26. Goldberg S.M., Bartido S.M., Gardner J.P., Guevara-Patino J.A., Montgomery S.C., Perales M.A., et al. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin Cancer Res 11 22 (2005) 8114-8121
27. Leitner W.W., Hwang L.N., deVeer M.J., Zhou A., Silverman R.H., Williams B.R., et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 9 1 (2003) 33-39
28. Mingozzi F., and High K.A. Immune responses to AAV in clinical trials. Curr Gene Ther 7 5 (2007) 316-324
29. Sumida S.M., Truitt D.M., Kishko M.G., Arthur J.C., Jackson S.S., Gorgone D.A., et al. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 78 6 (2004) 2666-2673
30. Kedl R.M., Kappler J.W., and Marrack P. Epitope dominance, competition and T cell affinity maturation. Curr Opin Immunol 15 1 (2003) 120-127
31. Kedl R.M., Schaefer B.C., Kappler J.W., and Marrack P. T cells down-modulate peptide-MHC complexes on APCs in vivo. Nat Immunol 3 1 (2002) 27-32
32. Willis R.A., Kappler J.W., and Marrack P.C. CD8 T cell competition for dendritic cells in vivo is an early event in activation. Proc Natl Acad Sci USA 103 32 (2006) 12063-12068
33. Chen W., Anton L.C., Bennink J.R., and Yewdell J.W. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 12 1 (2000) 83-93
34. Scherer A., Salathe M., and Bonhoeffer S. High epitope expression levels increase competition between T cells. PLoS Comput Biol 2 8 (2006) e109
35. Gallimore A., Hombach J., Dumrese T., Rammensee H.G., Zinkernagel R.M., and Hengartner H. A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells. Eur J Immunol 28 10 (1998) 3301-3311
36. Rechtsteiner G., Warger T., Hofmann M., Rammensee H.G., Schild H., and Radsak M.P. Precursor frequency can compensate for lower TCR expression in T cell competition during priming in vivo. Eur J Immunol 36 10 (2006) 2613-2623
37. Kedl R.M., Rees W.A., Hildeman D.A., Schaefer B., Mitchell T., Kappler J., et al. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 192 8 (2000) 1105-1113
38. Probst H.C., Dumrese T., and van den Broek M.F. Cutting edge: competition for APC by CTLs of different specificities is not functionally important during induction of antiviral responses. J Immunol 168 11 (2002) 5387-5391
39. Kastenmuller W., Gasteiger G., Gronau J.H., Baier R., Ljapoci R., Busch D.H., et al. Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination. J Exp Med 204 9 (2007) 2187-2198
40. Bos R., van Duikeren S., van Hall T., Lauwen M.M., Parrington M., Berinstein N.L., et al. Characterization of antigen-specific immune responses induced by canarypox virus vaccines. J Immunol 179 9 (2007) 6115-6122
41. Lundegaard C., Lamberth K., Harndahl M., Buus S., Lund O., and Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 36 July (Web Server issue) (2008) W509-W512
42. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23 9 (1993) 2242-2249